About
Minimally Invasive Treatment for Mitral Regurgitation
MitrAssist has developed an approach to treating patients with life-threatening mitral regurgitation (MR) that involves neither repair nor replacement. Instead, the companys proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssists valve-in-valve approach overcomes the various challenges of MR and offers an alternative treatment solution for all MR patients. Made from biomedical and biological materials, MitrAssists valve offers improved biocompatibility and patient recovery time.
Identity
| Name | MitrAssist |
|---|---|
| Slug | mitrassist |
| Type / kind | startup |
| Crunchbase ID | mitrassist |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7q_a4KDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2026 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Caesarea |
| HQ address | Alon Hatavor 20, Caesarea, Israel |
Web & social
| https://www.linkedin.com/company/2989684 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
cardiologyhospitalsdoctorsbiomaterialssurgerymedical-devicesvalvesminimally-invasive
Funding
| Total raised | $204.0M |
|---|---|
| Current stage | Series C |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}